2023
DOI: 10.1097/cp9.0000000000000056
|View full text |Cite
|
Sign up to set email alerts
|

Cancer treatment-related cardiotoxicity: a focus on sacubitril/valsartan

Abstract: Cardiotoxicity is the most dramatic complication of cancer therapies, and it results in the cessation of potentially life-saving antitumor treatment regimens and a poor survival prognosis in a nonnegligible proportion of patients. Angiotensin converting enzyme inhibitors (ACEIs) and β-blockers are effective in the treatment of cancer therapy-related cardiac dysfunction (CTRCD), whereas their roles in the prevention of cardiotoxicity are unclear. Sacubitril/valsartan, which is an angiotensin receptor-neprilysin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 89 publications
(180 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?